National Cancer Institute’s Bioinformatics Grid (caBIG) initiative is a network of infrastructure and tools that enables the collection, analysis and sharing of data and knowledge along the entire research pathway from laboratory bench to patient bedside.
By releasing the cell line data via caBIG, GlaxoSmithKline (GSK) could be enabling other cancer research institutions to save considerable drug development time and capital in their future cancer therapeutic research.
The genomic data being shared by GSK through caBIG come from cell lines derived from a variety of tumors, including breast, prostate, lung and ovarian cancers.